| abstract |
There is provided a glycosaminoglycan having anbackbone structure comprising a repetitive disaccharidenbearing a uronic acid residue and a glucosamine residue,nand having sulfate groups, wherein substantially nonsulfate group bound to the hydroxyl group at the 6-positionnof the glucosamine residue in the backbonenstructure is detected as determined by a chemicalndisaccharide analysis method in which thenglycosaminoglycan is decomposed with nitrous acid,nreacted with para-nitrophenylhydrazine and analyzed bynhigh performance liquid chromatography, and the molar %nof a uronic acid residue having a sulfate group at then2-position is not less than 45% relative to total uronicnacid residues, which is calculated from a disaccharidencomposition obtained by an enzymatic disaccharidenanalysis method in which the glycosaminoglycan isndigested with glycosaminoglycan-degrading enzymes andnanalyzed by high performance liquid chromatography. Thenglycosaminoglycan can be used as an active ingredient ofnphamaceuticals. |